Recent News

• 10.28.2026 - Palisade Bio Announces First Patient Dosed in Global Phase 2b ASCENTRA-UC Study Evaluating Once-Daily Oral PALI-2108 for the Treatment of Ulcerative Colitis
• 10.20.2026 - Palisade Bio Presents Rapid Endoscopic Improvement and New Translational Evidence for PALI-2108 in Inflammatory Bowel Disease at UEG Week 2026
• 10.12.2026 - Palisade Bio Presents New Clinical, Pharmacokinetic, Pharmacodynamic and Mechanistic Data Strengthening the Phase 2 Rationale for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at ACG 2026
• 09.04.2026 - Development of Mucosal Transcriptomic Signatures to Predict Response to the Microbiome-Activated Phosphodiesterase (PDE)-4 Inhibitor PALI-2108 in Ulcerative Colitis
• 09.04.2026 - Microbiome Beta-Glucuronidase Activity Does Not Limit Bioconversion or Pharmacokinetic Consistency of the Colon-Targeted PDE4 Prodrug PALI-2108 in Ulcerative Colitis
• 09.04.2026 - The Microbiome-Activated Phosphodiesterase (PDE)-4 Inhibitor, PALI-2108 Leads to Rapid Clinical and Histologic Improvement in Moderate-to-Severe Ulcerative Colitis: A Phase1a/1b Study
• 09.04.2026 - PALI-2108, a Next-Generation Oral PDE4 Inhibitor Prodrug, Demonstrates Localized Ileocolonic Exposure with Favorable Tolerability in IBD
• 09.04.2026 - Gut-Targeted Inhibition of Phosphodiesterase 4 with PALI-2108 Demonstrates Early Endoscopic and Biomarker Improvements in Fibrostenotic Crohn’s Disease: Results From a Phase 1b Study
• 08.10.2026 - Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development
• 07.10.2026 - Palisade Bio to Participate in the Leerink Partners Therapeutics Forum

Recent Filings

• 10.21.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.21.2026 - 3 Initial statement of beneficial ownership of securities
• 10.07.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.07.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.05.2026 - 4 Statement of changes in beneficial ownership of securities
• 08.21.2026 - 4 Statement of changes in beneficial ownership of securities
• 08.14.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.13.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.10.2026 - 8-K Current report
• 08.10.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]